学名: Infliximab (因福利美)  

商品牌子名: Remicade (类克)  

药物制造商: Centocor 

剂型: 针剂 (100毫克) 

香港注册编号: HK-51100

孕妇用药分级: C

药理: 缓解病情抗风湿药, 抑制甲型肿瘤坏死因子的药物。

用途: 活性克隆氏症, 类风湿性关节炎, 强直性脊椎炎及牛皮癣关节炎

剂量: 在接受过第一剂注射后，第二及第三剂注射将分别于之后第二及第六周进行。然后，每六-八周接受一次注射。医生会监察病人对药物的反应，并会视乎情况加密注射的次数(可能需要每四周接受一次注射)。

用药禁忌: 
心脏衰竭的患者
对Infliximab (因福利美)或任何成份(蔗糖、磷酸钠、聚山梨醇酯八十) 产生过敏者
对鼠蛋白质产生过敏
用药注意: 
严重感染包括肺结核、由真菌或细菌引起，并已扩散至全身的感染
心脏衰竭
常见副作用: 最常见的副作用是呼吸道感染(如支气管炎，窦道感染、感冒、喉咙发炎)、咳嗽、恶心、胃痛、背部疼痛、腹泻、头痛、头晕、疲倦、痕痒和尿道感染。
其它副作用: 部份病人会出现过敏反应:过敏反应的症状包括荨麻疹(皮肤红肿、痕痒)、呼吸困难、胸部疼痛、血压偏高或偏低。以及狼疮相似的征状。
药物相互作用: 不详
病患者及家属注意事项: 如接受治疗时受到感染，应该立刻通知医生查及尽早医治。
医管局药物分类: 专用药物
药物法例分类: P1S1S3（此药为医生处方药物，须由药剂师核实处方后配药）
注射用英夫利西单抗(类克) 100mg/瓶  6600元

Generic Name for REMICADE
Infliximab 100mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution; preservative-free.

Legal Classification:
Rx
Pharmacological Class for REMICADE
Tumor necrosis factor-α blocker.
Manufacturer of REMICADE
Janssen Biotech, Inc.
Indications for REMICADE
Severe chronic plaque psoriasis in adults who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.

Adult dose for REMICADE
Give by IV infusion over at least 2 hours. 5mg/kg at weeks 0, 2, 6, then once every 8 weeks.

Children's dosing for REMICADE
Not recommended.

Contraindications for REMICADE
Moderate to severe CHF (doses >5mg/kg). Allergy to murine proteins.

Warnings/Precautions for REMICADE
Increased risk of serious or fatal infections (eg, TB, bacterial sepsis, invasive fungal). Active infections: not recommended. Chronic or history of recurring infections or hematological abnormalities. Conditions that predispose to infection. Test for and treat latent tuberculosis prior to initiating therapy. Monitor closely if new infection, reactivation of hepatitis B virus (HBV), or blood dyscrasias develop; discontinue if serious infection, sepsis, HBV reactivation, or hematological abnormality develops. Discontinue if lupus-like syndrome with antibody formation, serious hypersensitivity reactions, or jaundice with liver enzymes ≥5xULN occurs. Mild CHF; discontinue if CHF occurs or worsens. CNS demyelinating or seizure disorders; discontinue if significant CNS effects occur. Malignancies. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for REMICADE
Concurrent anakinra, live vaccines, or other TNF blockers: not recommended. Immunosuppressants increase risk of infection.

Adverse Reactions for REMICADE
Infections, infusion reactions (esp. after a period of no treatment), headache, GI upset, fatigue, cough, fever, pain, dizziness, rash, pruritus, CHF, antibody formation; rare: malignancies (eg, lymphoma; esp children), optic neuritis, seizures, lupus-like syndrome, blood dyscrasias, hepatotoxicity.
How is REMICADE supplied?
Single-use vials—1

Related Disease:
Plaque psoriasis
Psoriasis